Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Bringing together the academic drug discovery community

Nature Reviews Drug Discovery volume 12, pages 811–812 (2013)Cite this article

Subjects

Abstract

The newly formed Academic Drug Discovery Consortium (ADDC) aims to support the growing numbers of university centres engaged in drug discovery that have emerged in response to recent changes in the drug discovery ecosystem.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Arrowsmith, J. Trial watch: Phase II failures: 2008–2010. Nature Rev. Drug Discov. 10, 328–329 (2011).

    Article  CAS  Google Scholar 

  2. Arrowsmith, J. Trial watch: Phase III and submission failures: 2007–2010. Nature Rev. Drug Discov. 10, 87 (2011).

    Article  CAS  Google Scholar 

  3. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–214 (2010).

    Article  CAS  Google Scholar 

  4. Begley, C. G. & Ellis, L. M. Drug development: Raise standards for preclinical cancer research. Nature 483, 531–553 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Barbara S. Slusher, P. Jeffrey Conn, Stephen Frye, Marcie Glicksman and Michelle Arkin: All authors are founders and board members of the ADDC.

Authors and Affiliations

  1. ADDC President. She is also the Director of the Brain Science Institute Neuro Translational Drug Discovery Program, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA.,

    Barbara S. Slusher

  2. ADDC Vice President. He is also the Director of the Vanderbilt Center for Neuroscience Drug Discovery, Nashville, Tennessee 37232-0697, USA.,

    P. Jeffrey Conn

  3. Director of The Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina, 27599, North Carolina, USA

    Stephen Frye

  4. Co-Director of the Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center and Brigham and Women's Hospital, Boston, 02139, Massachusetts, USA

    Marcie Glicksman

  5. Associate Director of the Small Molecule Discovery Center, University of California, San Francisco, 94158-2330, California, USA

    Michelle Arkin

Authors
  1. Barbara S. Slusher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Jeffrey Conn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen Frye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcie Glicksman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michelle Arkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara S. Slusher.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

ADDC

The NCATS Budget

Rights and permissions

Reprints and permissions

About this article

Cite this article

Slusher, B., Conn, P., Frye, S. et al. Bringing together the academic drug discovery community. Nat Rev Drug Discov 12, 811–812 (2013). https://doi.org/10.1038/nrd4155

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4155

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research